Literature DB >> 20946578

Immunomodulators as adjuvants for vaccines and antimicrobial therapy.

Erin F Nicholls1, Laurence Madera, Robert E W Hancock.   

Abstract

A highly effective strategy for combating infectious diseases is to enhance host defenses using immunomodulators, either preventatively, through vaccination, or therapeutically. The effectiveness of many vaccines currently in use is due in part to adjuvants, molecules that have little immunogenicity by themselves but which help enhance and appropriately skew the immune response to an antigen. The development of new vaccines necessitates the development of new types of adjuvants to ensure an appropriate immune response. Herein, we review commonly used vaccine adjuvants and discuss promising adjuvant candidates. We also discuss various other immunomodulators (namely cytokines, Toll-like receptor agonists, and host defense peptides) that are, or have potential to be, useful for antimicrobial therapies that exert their effects by boosting host immune responses rather than targeting pathogens directly.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20946578     DOI: 10.1111/j.1749-6632.2010.05787.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  33 in total

Review 1.  Modulating immunity as a therapy for bacterial infections.

Authors:  Robert E W Hancock; Anastasia Nijnik; Dana J Philpott
Journal:  Nat Rev Microbiol       Date:  2012-03-16       Impact factor: 60.633

Review 2.  Immune modulation by multifaceted cationic host defense (antimicrobial) peptides.

Authors:  Ashley L Hilchie; Kelli Wuerth; Robert E W Hancock
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

3.  Amphipathic antimicrobial piscidin in magnetically aligned lipid bilayers.

Authors:  Anna A De Angelis; Christopher V Grant; Matthew K Baxter; Jason A McGavin; Stanley J Opella; Myriam L Cotten
Journal:  Biophys J       Date:  2011-09-07       Impact factor: 4.033

Review 4.  Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.

Authors:  Maria Luisa Mangoni; Yechiel Shai
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

Review 5.  Hypothesis driven development of new adjuvants: short peptides as immunomodulators.

Authors:  Jessica C Dong; Gary P Kobinger
Journal:  Hum Vaccin Immunother       Date:  2013-04-01       Impact factor: 3.452

Review 6.  Modulation of toll-like receptor signaling by antimicrobial peptides.

Authors:  Ernest Y Lee; Michelle W Lee; Gerard C L Wong
Journal:  Semin Cell Dev Biol       Date:  2018-02-12       Impact factor: 7.727

Review 7.  Current progress in development of hepatitis C virus vaccines.

Authors:  T Jake Liang
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

8.  Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Caixia Shen; Peter Andersen; Robert C Brunham
Journal:  Infect Immun       Date:  2012-01-30       Impact factor: 3.441

Review 9.  Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Expert Rev Vaccines       Date:  2016-03-21       Impact factor: 5.217

10.  Effect of lipopolysaccharide (LPS) from Ochrobactrum intermedium on sheep experimentally infected with Fasciola hepatica.

Authors:  J M Martínez-Pérez; D Robles-Pérez; F Valcárcel-Sancho; A M González-Guirado; I Casanova-García de Castro; J M Nieto-Martínez; F A Rojo-Vázquez; M Martínez-Valladares
Journal:  Parasitol Res       Date:  2013-06-06       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.